Compound Evidence File
#EC-2026-0231
P21
Filed under Peptides. The bureau holds 151 laboratory returns for this compound from 60 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
60 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 10.0 | 10.0 | 10.0 | 13 Jun 2025 | 13 Jun 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 9.4 | 9.4 | 9.4 | 13 Jun 2025 | 13 Jun 2025 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 9.0 | 9.0 | 9.0 | 20 Jun 2025 | 20 Jun 2025 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 9.0 | 9.0 | 9.0 | 24 Apr 2025 | 24 Apr 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.7 | 7.3 | 10.0 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.4 | 6.2 | 9.5 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.2 | 7.3 | 9.0 | 21 May 2026 | 21 May 2026 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 2 | 8.1 | 7.9 | 8.3 | 14 Jan 2025 | 24 May 2026 |
| Zztai PeptideCASE #VI-2026-0192 | X | 1 | 8.1 | 8.1 | 8.1 | 11 Jun 2025 | 11 Jun 2025 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 8.0 | 8.0 | 8.0 | 27 Feb 2025 | 27 Feb 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 7.9 | 6.5 | 9.0 | 21 May 2026 | 21 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 2 | 7.9 | 6.2 | 9.6 | 13 Feb 2025 | 17 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 2 | 7.8 | 6.8 | 8.8 | 23 May 2026 | 23 May 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 2 | 7.8 | 7.6 | 8.0 | 25 Apr 2025 | 21 May 2026 |
| NexaphCASE #VI-2026-0944 | X | 11 | 7.6 | 4.6 | 10.0 | 3 Jul 2025 | 25 May 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 2 | 7.6 | 6.2 | 9.0 | 21 May 2025 | 21 May 2026 |
| HK PeptidesCASE #VI-2026-0140 | X | 4 | 7.5 | 5.3 | 9.8 | 2 Jul 2025 | 20 May 2026 |
| Paramount PeptidesCASE #VI-2026-0550 | X | 3 | 7.4 | 7.0 | 7.6 | 2 Jul 2025 | 17 May 2026 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 7.2 | 7.2 | 7.2 | 25 Apr 2025 | 25 Apr 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 8 | 7.0 | 4.5 | 8.2 | 13 Jun 2025 | 21 May 2026 |
| Shanxi Qianyecao Biotech QYCCASE #VI-2026-0189 | X | 6 | 7.0 | 5.8 | 9.7 | 28 Mar 2025 | 25 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 2 | 7.0 | 4.4 | 9.6 | 20 Jun 2025 | 24 May 2026 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 4 | 6.9 | 6.0 | 9.2 | 2 Apr 2025 | 25 May 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 6.9 | 6.9 | 6.9 | 13 Feb 2025 | 13 Feb 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 1 | 6.9 | 6.9 | 6.9 | 24 Apr 2025 | 24 Apr 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 6.9 | 6.9 | 6.9 | 17 Dec 2024 | 17 Dec 2024 |
| Reta-PeptideCASE #VI-2026-0756 | X | 11 | 6.8 | 4.2 | 10.0 | 14 Jan 2025 | 20 May 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 6.8 | 4.9 | 8.6 | 7 May 2025 | 23 May 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 6.7 | 6.7 | 6.7 | 14 Jan 2025 | 14 Jan 2025 |
| PeptiAtlasCASE #VI-2026-0739 | X | 1 | 6.7 | 6.7 | 6.7 | 17 Dec 2024 | 17 Dec 2024 |
| HXNetCASE #VI-2026-0061 | X | 6 | 6.6 | 4.5 | 7.7 | 20 Jun 2025 | 21 May 2026 |
| Peptide CraftersCASE #VI-2026-0994 | X | 2 | 6.6 | 5.0 | 8.2 | 25 Apr 2025 | 20 May 2026 |
| Mix PeptidesCASE #VI-2026-0699 | X | 2 | 6.5 | 6.5 | 6.5 | 21 May 2025 | 17 May 2026 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 6.5 | 6.5 | 6.5 | 27 Feb 2025 | 27 Feb 2025 |
| Peptide-SCASE #VI-2026-0111 | X | 8 | 6.3 | 5.3 | 7.8 | 17 Dec 2024 | 19 Jan 2026 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 6.3 | 6.3 | 6.3 | 7 May 2025 | 7 May 2025 |
| Shenzhen Jiechuang TradingCASE #VI-2026-0292 | X | 1 | 6.1 | 6.1 | 6.1 | 27 Feb 2025 | 27 Feb 2025 |
| LSPLCASE #VI-2026-0523 | X | 2 | 6.0 | 5.6 | 6.5 | 28 Mar 2025 | 23 May 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 1 | 5.9 | 5.9 | 5.9 | 25 Apr 2025 | 25 Apr 2025 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 5.7 | 5.7 | 5.7 | 17 Dec 2024 | 17 Dec 2024 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 5.7 | 5.7 | 5.7 | 6 May 2025 | 6 May 2025 |
| Elite Research USACASE #VI-2026-0267 | X | 3 | 5.6 | 5.0 | 6.7 | 14 Jan 2025 | 19 Jan 2026 |
| Platinum CryoCASE #VI-2026-0406 | X | 2 | 5.6 | 3.2 | 8.0 | 3 Jul 2025 | 25 May 2026 |
| Champion PeptideCASE #VI-2026-0909 | X | 1 | 5.6 | 5.6 | 5.6 | 13 Feb 2025 | 13 Feb 2025 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 5.4 | 5.4 | 5.4 | 21 May 2025 | 21 May 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 5.3 | 5.3 | 5.3 | 24 Apr 2025 | 24 Apr 2025 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 5.3 | 5.3 | 5.3 | 2 Jul 2025 | 2 Jul 2025 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 5.2 | 5.2 | 5.2 | 9 Jun 2025 | 9 Jun 2025 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 5.0 | 5.0 | 5.0 | 20 Jun 2025 | 20 Jun 2025 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 4.9 | 4.9 | 4.9 | 28 Mar 2025 | 28 Mar 2025 |
| Accelerate LabsCASE #VI-2026-0686 | X | 1 | 4.6 | 4.6 | 4.6 | 25 Apr 2025 | 25 Apr 2025 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 4.3 | 4.3 | 4.3 | 27 Feb 2025 | 27 Feb 2025 |
| Qingdao VitaConin International TradingCASE #VI-2026-0504 | X | 1 | 4.0 | 4.0 | 4.0 | 21 May 2025 | 21 May 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 3.9 | 3.9 | 3.9 | 16 Mar 2025 | 16 Mar 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 1 | 3.1 | 3.1 | 3.1 | 9 Jun 2025 | 9 Jun 2025 |
| PepLab SolutionsCASE #VI-2026-0431 | X | 1 | 1.1 | 1.1 | 1.1 | 28 Mar 2025 | 28 Mar 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.4 | 0.4 | 0.4 | 17 Dec 2024 | 17 Dec 2024 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.4 | 0.4 | 0.4 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for P21 alone.